$NTLA

ARK Invest, led by Cathie Wood, bought shares of Robinhood Markets (HOOD) and the 3iQ Solana Staking ETF (SOLQ.U) amid a market selloff triggered by strong U.S. jobs data, raising expectations of a Fed rate hike. ARKG added 28,589 HOOD shares ($3.49M) and 3,392 SOLQ.U shares ($28,120). The Dow, S&P 500, and Nasdaq fell 0.51%, 0.38%, and 0.29% respectively.

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points CAMBRIDGE, Mass., S

Intellia Therapeutics (NTLA) secured a $400 million debt facility from OrbiMed, with $75 million funded at closing and $225 million tied to milestones for lonvo-z, a CRISPR gene-editing therapy. The facility provides financial flexibility for lonvo-z's development and potential U.S. launch for hereditary angioedema (HAE). NTLA shares are up 0.63% at $12.76.

Ark Invest's Cathie Wood added to existing holdings, including Nvidia (NVDA), Broadcom (AVGO), and Intellia Therapeutics (NTLA). Nvidia reported strong Q2 results with $96.2B revenue and raised guidance. Broadcom expects 85% revenue growth. Intellia Therapeutics received a Buy rating with a $24 price target. Ark's Genomic Revolution ETF (ARKG) gained 64% YTD.

Intellia Therapeutics (NTLA) stock rose 5% premarket after positive Phase 3 data for its CRISPR-based therapy, Lonvo-z, showed significant reductions in hereditary angioedema (HAE) attacks. The company reported 89% and 91% reductions in attacks requiring rescue medication and moderate-to-severe attacks, respectively, compared to placebo. Intellia aims for FDA approval and U.S. launch in early 2027.

Intellia Therapeutics (NTLA) stock rose 35% ahead of Phase 3 trial results for its gene-editing therapy, Lonvo-z, which targets hereditary angioedema. The company reports topline results Monday. Earlier studies showed significant reductions in attack frequency. Investors await the first Phase 3 test of an in-body CRISPR therapy. NTLA stock is up 67% over the past year.

Cathie Wood's Ark Invest increased stakes in Nvidia, Broadcom, and Intellia Therapeutics. Nvidia reported strong earnings, with revenue up 106% and raised guidance. Broadcom is expected to show accelerating growth. Intellia, unprofitable but with bullish long-term prospects, saw an analyst upgrade.

A phase 3 trial showed that a single dose of lonvoguran ziclumeran (lonvo-z or NTLA-2002) reduced hereditary angioedema attacks by 87% compared to placebo. 62% of treated patients remained attack-free. Adverse events were mostly mild, with no serious events reported. The study was funded by Intellia Therapeutics.

Intellia (NTLA) discussed Q2 2026 updates for lonvo-z in hereditary angioedema, citing a New England Journal manuscript showing a 23-point improvement in quality-of-life score and attack-rate reductions in the lonvo-z arm, with all patients remaining free of long-term prophylaxis as of the data cutoff. The company expects FDA BLA acceptance for lonvo-z by year-end and plans a U.S. launch in H1 next year. It also resumed Q3 Phase III enrollment for nex-z after resolving clinical holds.

Intellia Therapeutics (NASDAQ:NTLA) shares rose 11% to $11.94 after its latest quarterly results. The company reported revenue of $7.7m, about 41% below analyst forecasts, while its statutory loss of $0.80 per share matched expectations. Analysts cut 2026 revenue to $52.3m (down 12%) and raised/kept losses at $3.18 per share, lowering the average price target 8.5% to $23.94.